Deadline Approaching: Flywire Corporation (FLYW) Investors Who Lost Money Urged To Contact Law Offices of Howard G. Smith
IF YOU ARE AN INVESTOR WHO SUFFERED A LOSS IN FLYWIRE CORPORATION (FLYW), CONTACT THE LAW OFFICES OF HOWARD G. SMITH TO PARTICIPATE IN THE ONGOING SECURITIES FRAUD LAWSUIT.
Contact the Law Offices of Howard G. Smith to discuss your legal rights by email at howardsmith@howardsmithlaw.com, by telephone at (215) 638-4847 or visit our website at www.howardsmithlaw.com.
What Happened?
On February 25, 2025, after market hours, Flywire released its fourth quarter 2024 financial results, missing consensus estimates, citing 'a complex macro environment with significant headwinds' and stating that the Company's business in the education sector had significantly deteriorated due to worsening permit- and visa-related headwinds, including 'double digit declines in student visa issuance in our big four geographic markets,' with 'continued visa policy restrictions' anticipated in 2025. The Company further announced a restructuring plan that included a 10% reduction in its workforce. Additionally, the Company reduced its 2025 guidance.
On this news, Flywire's stock price fell $6.59, or 37.4%, to close at $11.05 per share on February 26, 2025, thereby injuring investors.
What Is The Lawsuit About?
The complaint filed in this class action alleges that throughout the Class Period, Defendants made materially false and/or misleading statements, as well as failed to disclose material adverse facts about the Company's business, operations, and prospects. Specifically, Defendants failed to disclose to investors that: (1) the strength and sustainability of Flywire's revenue growth was overstated; (2) the negative impact that permit- and visa-related restrictions were having and were likely to have on Flywire's business was understated; and (3) as a result, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis at all relevant times.
If you purchased or otherwise acquired Flywire securities during the Class Period, you may move the Court no later than September 23, 2025 to ask the Court to appoint you as lead plaintiff if you meet certain legal requirements.
Contact Us To Participate or Learn More:
If you wish to learn more about this class action, or if you have any questions concerning this announcement or your rights or interests with respect to these matters, please contact us:
Law Offices of Howard G. Smith,
3070 Bristol Pike, Suite 112,
Bensalem, Pennsylvania 19020,
Telephone: (215) 638-4847
Email: howardsmith@howardsmithlaw.com,
Visit our website at: www.howardsmithlaw.com.
To be a member of the class action you need not take any action at this time; you may retain counsel of your choice or take no action and remain an absent member of the class action.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and ethical rules.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
10 minutes ago
- Globe and Mail
Zacks Investment Ideas feature highlights: CVS Health, Johnson & Johnson and Tenet Healthcare
For Immediate Release Chicago, IL – August 4, 2025 – Today, Zacks Investment Ideas feature highlights CVS Health CVS, Johnson & Johnson JNJ and Tenet Healthcare THC. 3 Medical Stocks to Consider as Markets Take a Breather The broader indexes have cooled off in the last few trading sessions after what was another pleasant month for the stock market in July. While the market has been able to shrug off trade war concerns on the way to a historic rebound, President Trump has officially signed an executive order to hit most of the United States' trading partners with tariff hikes, which ignited a pullback on Friday as July's Jobs Report came in weaker than expected. Considering the benchmark S&P 500 and the tech-centric Nasdaq looked due for a breather after spiking more than +10% in the last three months, investors may be scoping out some defensive positions. That said, these medical sector stocks may continue to provide this defensive safety, as there will always be a constant need for health care. CVS Health Zacks Rank #2 (Buy) CVS Health's transformation into an innovative pharmacy company with integrated offerings across the entire spectrum of pharmacy care is paying off. Thanks to strong earnings, raised guidance, and renewed investor confidence, CVS stock has surged over +30% this year but still trades at just 10X forward earnings and offers a very generous 4.28% annual dividend yield. In addition to sporting a Zacks Rank #2 (Buy), CVS stock currently checks an overall 'A' VGM Zacks Style Scores grade for the combination of Value, Growth, and Momentum. Johnson & Johnson Zacks Rank #2 (Buy) Pharmaceutical giant Johnson & Johnson checks the value box, with a reasonable 15.1X forward earnings multiple and a 3.16% annual dividend yield. Furthermore, investors seemed to have flocked to Johnson & Johnson stock earlier in the year during heightened market volatility, and JNJ is still up +15% in 2025 to top the S&P 500 and Nasdaq's returns of roughly +7%. Although Johnson & Johnson's growth has slowed, steady top and bottom line expansion is still in the forecast, and the medical leader has one of the most diversified business models. Having more than 275 subsidiaries, Johnson & Johnson's pipeline of drugs/treatments covers neuroscience and mental health, oncology, immunology, pulmonary hypertension, cardiovascular, rare, and infectious diseases. Tenet Healthcare Zacks Rank #1 (Strong Buy) We'll round out the list with Tenet Healthcare, an investor-owned health care services company that owns and operates general hospitals and health care facilities for urban and rural communities in numerous states. Boasting a Zacks Rank #1 (Strong Buy), THC stock is benefiting from a very pleasant trend of positive earnings estimate revisions. With Tenet Healthcare's annual earnings now expected to leap 25% in fiscal 2025 to $14.92 per share, it's noteworthy that these EPS revisions have climbed 17% in the last 60 days from estimates of $12.69 two months ago. Plus, THC is up +25% YTD and trades at 10X forward earnings. Strongly suggesting Tenet Healthcare's impressive stock performance should continue, FY26 EPS is projected to expand another 4% to $15.48, and estimates have spiked 14% in the last 60 days. On top of being a 'feel-good' investment in regard to Tenet Healthcare reaching underserved communities, THC checks the fundamental trading boxes with an 'A' VGM Zacks Style Scores grade. Bottom Line Hopefully, the excitement for AI-driven growth will continue to push the broader market higher, but these top medical stocks can provide the defensive safety that investors may need with volatility starting to resurface amid President Trump's tariff hikes and last month's unfavorable jobs report. Why Haven't You Looked at Zacks' Top Stocks? Since 2000, our top stock-picking strategies have blown away the S&P's +7.7% average gain per year. Amazingly, they soared with average gains of +48.4%, +50.2% and +56.7% per year. Today you can access their live picks without cost or obligation. See Stocks Free >> Media Contact Zacks Investment Research 800-767-3771 ext. 9339 support@ Past performance is no guarantee of future results. Inherent in any investment is the potential for loss. This material is being provided for informational purposes only and nothing herein constitutes investment, legal, accounting or tax advice, or a recommendation to buy, sell or hold a security. No recommendation or advice is being given as to whether any investment is suitable for a particular investor. It should not be assumed that any investments in securities, companies, sectors or markets identified and described were or will be profitable. All information is current as of the date of herein and is subject to change without notice. Any views or opinions expressed may not reflect those of the firm as a whole. Zacks Investment Research does not engage in investment banking, market making or asset management activities of any securities. These returns are from hypothetical portfolios consisting of stocks with Zacks Rank = 1 that were rebalanced monthly with zero transaction costs. These are not the returns of actual portfolios of stocks. The S&P 500 is an unmanaged index. Visit for information about the performance numbers displayed in this press release. Zacks Names #1 Semiconductor Stock This under-the-radar company specializes in semiconductor products that titans like NVIDIA don't build. It's uniquely positioned to take advantage of the next growth stage of this market. And it's just beginning to enter the spotlight, which is exactly where you want to be. With strong earnings growth and an expanding customer base, it's positioned to feed the rampant demand for Artificial Intelligence, Machine Learning, and Internet of Things. Global semiconductor manufacturing is projected to explode from $452 billion in 2021 to $971 billion by 2028. See This Stock Now for Free >> Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Johnson & Johnson (JNJ): Free Stock Analysis Report CVS Health Corporation (CVS): Free Stock Analysis Report
CTV News
10 minutes ago
- CTV News
Canada's economy is showing ‘resilience' against U.S. tariffs. Why?
Canadian and American flags fly near the Ambassador Bridge at the Canada-U.S. border crossing in Windsor, Ont., on Saturday, March 21, 2020. THE CANADIAN PRESS/Rob Gurdebeke OTTAWA — 'Some resilience' — those were the two words Bank of Canada governor Tiff Macklem used last week to describe how the Canadian economy is holding up under the weight of U.S. tariffs. Just a few days later, U.S. President Donald Trump added 35 per cent tariffs on Canadian goods to a running tally that includes hefty duties on steel, aluminum, automobiles and, more recently, semi-finished copper. With tariffs piling up over the past few months, economists say Canada's economy is starting to show cracks — but few signs of collapse. TD Bank economist Marc Ercolao conceded it's a 'bit of surprise' to see the economy holding up against a massive disruption from Canada's largest trading partner. 'Many months ago, ourselves — as well as other economic forecasters — had an outlook for a much weaker Canadian economy. Obviously, that isn't manifesting now,' he said in an interview. 'We are avoiding the worst-case scenario.' What are tariffs doing to the economy? On Thursday, Statistics Canada gave a glimpse at how the economy wrapped up the second quarter of the year when many of those tariffs came into full effect. While the agency sees a couple of small contractions in real gross domestic product by industry in April and May, its flash estimates show the economy rebounding somewhat in June. If those early readings pan out, StatCan said that would be good enough for flat growth overall on the quarter. Some of those results are distorted by volatility — businesses rushing to get ahead of tariffs boosted activity in the first quarter, and that's giving way to weakness in the second quarter, for example. It's still hard to pinpoint exact impacts tied to tariffs, Ercolao said, but a broad trend is emerging. 'What we can say over the last six months or so is that economic activity is somewhat flatlining,' he said. Services sectors are holding up relatively well, but Ercolao said export-heavy industries such as manufacturing and transportation are bearing the brunt of the impact. In an attempt to shore up some of that weakness, the federal government has announced various programs to support tariff-affected workers and broader plans to accelerate defence and infrastructure spending. Macklem noted during his press conference Wednesday that business and consumer confidence are still low, but have improved according to the central bank's recent surveys. And while some trade-exposed sectors have faced job losses and the unemployment has generally trended upward to nearly seven per cent, employers elsewhere in the economy continue to expand their payrolls. 'Consumption is still growing,' Macklem said. 'It's growing modestly. It's certainly being restrained by the uncertainty caused by tariffs. But it is growing and we expect that to continue through the third and fourth quarters.' Will Canada hit a recession? Last week the Bank of Canada kept its policy interest rate unchanged at 2.75 per cent in a third consecutive decision. If the central bank were panicked about the Canadian economy's ability to withstand U.S. tariffs, Ercolao argued it would likely have lowered that rate. The past week's GDP readings were good enough for BMO to raise its outlook for the third quarter into positive territory. Forecasters at the bank now expect Canada will avoid a technical recession this year. BMO chief economist Doug Porter said in a note to clients Friday that Ottawa's personal tax cut at the start of the month and robust demand for domestic travel amid the trade war will boost the economy this quarter, as will 'the less-dire sentiment' around economic forecasts. Some other forecasters continue to pencil a tariff-induced recession into their outlooks. In the Bank of Canada's monetary policy report released alongside the rate decision, it outlined one scenario for the economy assuming the tariff situation remains largely status quo. Canada avoids a recession in that outcome. Growth in 2025 and 2026 remains overall positive, but half a percentage point lower than it would've been without the weight of tariffs. Macklem told reporters that the Bank of Canada would expect the economy to keep growing even with today's tariffs in place, 'but it'll be on a permanently lower path.' 'Unfortunately, the sad reality is that tariffs mean the economy is going to work less efficiently,' he said. What about the new tariffs? Porter said in his note that the actual impact of Trump's new 35 per cent tariff on Canada's economy could be less than headline figure suggests. Because of a carve-out for Canadian exports that are compliant with CUSMA, BMO sees the effective U.S. tariff rate at roughly seven per cent under the new duties, less than a percentage point higher than where it stood before Friday. But with CUSMA up for renegotiation in 2026, Porter said that 35 per cent tariff rate could loom as a 'cudgel' over negotiations — taking full effect if the trade agreement expires without a new deal in place. The Bank of Canada published a separate 'escalation' scenario this week that would see the United States remove Canada's CUSMA exemption as it ramps up global tariffs. Real GDP would drop an extra 1.25 per cent by 2027 in this more severe case; Porter said that this outcome would be 'serious for sure, but far from disastrous.' Ercolao said much of the tariff doom-and-gloom earlier in the year was tied to the speed at which those import duties would be imposed. But the on-again, off-again nature of U.S. trade restrictions to date has given businesses time to adapt to the new way of doing business and constant delays in implementation, he said. 'If we go back to when Trump began his presidency, had he went 100 per cent on his tariff plan right away, we probably would have seen a deep economic contraction just because it would have been so sudden,' Ercolao explained. 'Now we've been afforded that time to at least try to mitigate some of the negative impacts from what these tariffs were expected to do to the Canadian economy.' This report by The Canadian Press was first published Aug. 4, 2025. Craig Lord, The Canadian Press
National Post
10 minutes ago
- National Post
Blue J Announces $122M Series D Financing Led By Oak HC/FT and Sapphire Ventures
Article content Blue J doubles revenue and customer base in first half of 2025, delivering comprehensive tax research to tens of thousands of tax professionals Article content TORONTO — Blue J, a leading GenAI tax research platform, today announced it has raised $122 million in U.S. dollars in a Series D funding round led by Oak HC/FT and Sapphire Ventures, with participation from Intrepid Growth Partners, and previous investors Ten Coves Capital and Coming seven months after Blue J's Series C round, this investment signals a clear market consensus that Blue J is the breakout winner in its category. Article content Article content 'We're thrilled to partner with Sapphire Ventures, Oak HC/FT, Ten Coves, and Intrepid Growth Partners — firms with exceptional track records of backing market-defining companies,' said Benjamin Alarie, CEO and co-founder of Blue J. 'Their commitment is a powerful endorsement of our vision to transform tax research. With this capital and industry support, we will accelerate innovation and deliver even greater value to tax professionals. We are building the future of tax. This is just the beginning.' Article content 'Tax research has long been a cumbersome, time-consuming task,' said Allen Miller, Partner at Oak HC/FT. 'Blue J has solved this challenge with an elegant AI solution that dramatically accelerates research while raising the bar for accuracy. We believe Blue J will become the new standard for complex tax questions — and we're proud to support Ben and the team in their next stage of growth.' Article content 'Blue J is exactly what we look for in vertical AI: deep domain expertise, proprietary data and a product that drives meaningful business impact,' said Cathy Gao, Partner at Sapphire Ventures and Blue J's newest board member. 'By applying generative AI to decades of tax rulings, Blue J reduces research that once took hours to just minutes. It's already trusted by enterprise clients, embraced by top firms, and loved by many practitioners. We believe their momentum shows the industry is ready, and we're proud to back Blue J as they build the operating layer for global tax cognition.' Article content Blue J's platform leverages advanced generative AI to deliver instant, reliable answers to complex tax questions spanning U.S. federal, state, and local tax (SALT), as well as Canadian and UK tax law. Built on a rigorously curated database of authoritative tax law, Blue J's system continuously improves by learning from millions of user queries each year. The result: practitioners can navigate even the most challenging tax issues with unmatched confidence and speed. Article content Unlike legacy keyword-based research tools, Blue J lets users ask tax questions conversationally, with no arcane syntax required. The intuitive interface delivers answers in seconds, complete with relevant source citations, making Blue J the industry's most user-friendly tax research platform. More than 70% of users log in weekly, and Blue J's Net Promoter Score (NPS) is consistently in the mid-70s. Article content In the first half of 2025, the company more than doubled its revenue and customer base, now serving tens of thousands of tax professionals across thousands of organizations that rely on Blue J for authoritative tax research, analysis, and answers. With the Series D funding, Blue J will further accelerate team expansion, product development, and market reach. Article content The company has proudly earned recognition from other generative AI leaders. 'Blue J is a leading example of effective AI deployment in one of the most complex information domains,' said Marc Manara, Head of Startups at OpenAI. 'By leveraging OpenAI's latest models, Blue J has elevated the standard for accuracy, trust, and insight in tax research. We're excited to continue working together at the forefront of innovation.' Article content This Series D follows Blue J's December 2024 Series C and comes during a period of rapid acceleration for the company. Since January 2025, Blue J has grown to over 80 employees and more than doubled its rate of new customer acquisition. With this new investment and market momentum, Blue J is poised to set the new standard for AI-driven tax research as global tax complexity continues to rise. Article content About Blue J Article content Founded in 2015, Blue J is redefining tax research with generative AI. Trusted by tax professionals across accounting firms, law firms, corporations, and government, Blue J delivers fast, verifiable analysis and answers to even the most complex tax questions — empowering experts to serve with clarity and confidence. With an intuitive conversational interface and a rigorously curated library of authoritative sources, Blue J is transforming how tax professionals work and make decisions. Leading organizations trust Blue J to streamline their research workflow and enhance decision-making accuracy. For more information, visit Article content About Oak HC/FT Article content Oak HC/FT is a venture and growth equity firm specializing in investments in fintech and healthcare. Using partnership as a foundation, Oak HC/FT guides companies and founders at every stage, from seed to growth, to create businesses that make a measurable and lasting impact. Founded in 2014, Oak HC/FT has invested in over 105 portfolio companies and has over $5.3 billion in assets under management. Oak HC/FT is headquartered in Stamford, CT, with an office in San Francisco, CA. Follow Oak HC/FT on LinkedIn and X and learn more at Article content About Sapphire Article content Sapphire is a global software venture capital firm with over $11 billion in AUM and team members across Austin, London, Menlo Park and San Francisco. For more than two decades, Sapphire has partnered with visionary management teams and venture funds to back companies of consequence. Since its founding, Sapphire has invested in more than 170 companies globally resulting in more than 30 Public Listings and 45 acquisitions. The firm's investment strategies — Sapphire Ventures, Sapphire Partners and Sapphire Sport — are focused on scaling companies and venture funds, elevating them to become category leaders. Sapphire's Portfolio Growth team of experienced operators delivers a strategic blend of value-add services, tools and resources designed to support portfolio company leaders as they scale. Article content Article content Article content Article content Article content Contacts Article content Media Contacts: Article content Blue J Article content Article content Article content
